ZA200106972B - Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction. - Google Patents

Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction. Download PDF

Info

Publication number
ZA200106972B
ZA200106972B ZA200106972A ZA200106972A ZA200106972B ZA 200106972 B ZA200106972 B ZA 200106972B ZA 200106972 A ZA200106972 A ZA 200106972A ZA 200106972 A ZA200106972 A ZA 200106972A ZA 200106972 B ZA200106972 B ZA 200106972B
Authority
ZA
South Africa
Prior art keywords
compound
formula
group
het
alkyl
Prior art date
Application number
ZA200106972A
Other languages
English (en)
Inventor
Stilz Hans Ulrich
Martin Gerl
Gary A Flynn
Magda Stankova
Robert A Binnie
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of ZA200106972B publication Critical patent/ZA200106972B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
ZA200106972A 1999-03-01 2000-02-19 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction. ZA200106972B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99103869A EP1070727A1 (en) 1999-03-01 1999-03-01 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction

Publications (1)

Publication Number Publication Date
ZA200106972B true ZA200106972B (en) 2002-08-07

Family

ID=8237658

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200106972A ZA200106972B (en) 1999-03-01 2000-02-19 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction.

Country Status (21)

Country Link
US (1) US6365572B1 (id)
EP (4) EP1070727A1 (id)
JP (1) JP4542272B2 (id)
CN (2) CN100441594C (id)
AT (2) ATE370969T1 (id)
AU (1) AU779779B2 (id)
BR (1) BR0008647A (id)
CA (1) CA2363958C (id)
CY (1) CY1106967T1 (id)
CZ (1) CZ300736B6 (id)
DE (2) DE60036087T2 (id)
DK (1) DK1157040T3 (id)
ES (1) ES2288844T3 (id)
HU (1) HU228993B1 (id)
ID (1) ID30183A (id)
PL (2) PL202887B1 (id)
PT (1) PT1157040E (id)
RU (2) RU2380371C2 (id)
TR (2) TR200800782T2 (id)
WO (1) WO2000052051A1 (id)
ZA (1) ZA200106972B (id)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070727A1 (en) * 1999-03-01 2001-01-24 Aventis Pharma Deutschland GmbH Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
US20080241835A1 (en) * 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
JP2003525595A (ja) * 1999-11-01 2003-09-02 キュラゲン コーポレイション 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
WO2004093892A2 (en) 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
FR2947452B1 (fr) * 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-serine et/ou l-asparagine et/ou l-valine pour prevenir et/ou au traiter des reactions inflammatoires de la peau.
RU2622018C1 (ru) * 2016-06-16 2017-06-08 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Быстро растворяющаяся трансбуккальная плёнка для лечения депрессивных расстройств, тревоги и расстройств адаптации
CA3045887A1 (en) * 2016-12-09 2018-06-14 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8821785D0 (en) * 1988-09-16 1988-10-19 Nycomed As Peptide compounds
RU2145233C1 (ru) * 1990-07-02 2000-02-10 Дзе Аризона Борд оф Риджентс Неупорядоченная библиотека пептидов, способ ее получения и способ идентификации пептида, синтезированного твердофазным синтезом
US5493008A (en) * 1994-08-15 1996-02-20 The University Of Virginia Patent Foundation Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
DE19701607A1 (de) 1997-01-17 1998-07-23 Hoechst Ag Anitkörper, die an die Nidogen-Bindungsdomäne des Laminins binden, deren Herstellung und Verwendung
EP1070727A1 (en) * 1999-03-01 2001-01-24 Aventis Pharma Deutschland GmbH Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction

Also Published As

Publication number Publication date
TR200102560T2 (tr) 2002-01-21
PL351483A1 (en) 2003-04-22
RU2262509C2 (ru) 2005-10-20
RU2380371C2 (ru) 2010-01-27
JP2002539092A (ja) 2002-11-19
ATE477271T1 (de) 2010-08-15
EP1157040B1 (en) 2007-08-22
ATE370969T1 (de) 2007-09-15
CN1342167A (zh) 2002-03-27
HU228993B1 (en) 2013-07-29
CZ300736B6 (cs) 2009-07-29
DK1157040T3 (da) 2007-12-03
TR200800782T2 (tr) 2008-08-21
PL208356B1 (pl) 2011-04-29
CN1775801A (zh) 2006-05-24
WO2000052051A1 (en) 2000-09-08
ID30183A (id) 2001-11-08
AU779779B2 (en) 2005-02-10
US6365572B1 (en) 2002-04-02
DE60044832D1 (de) 2010-09-23
RU2005114905A (ru) 2006-11-20
HK1042499A1 (en) 2002-08-16
EP1157040A1 (en) 2001-11-28
ES2288844T3 (es) 2008-02-01
PT1157040E (pt) 2007-09-25
CA2363958A1 (en) 2000-09-08
PL202887B1 (pl) 2009-08-31
EP1845106A1 (en) 2007-10-17
DE60036087T2 (de) 2008-05-15
CZ20013063A3 (cs) 2001-11-14
HUP0200192A3 (en) 2002-09-30
CY1106967T1 (el) 2012-01-25
DE60036087D1 (de) 2007-10-04
EP1070727A1 (en) 2001-01-24
CA2363958C (en) 2012-04-17
AU3157700A (en) 2000-09-21
HUP0200192A2 (en) 2002-06-29
CN100441594C (zh) 2008-12-10
CN1237075C (zh) 2006-01-18
HK1087126A1 (zh) 2006-10-06
EP2239270A3 (en) 2011-01-12
JP4542272B2 (ja) 2010-09-08
BR0008647A (pt) 2002-01-22
EP1845106B1 (en) 2010-08-11
EP2239270A2 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
JP2945680B2 (ja) ペプチド誘導体およびその用途
JP2002524571A (ja) ＶＩＩａ因子阻害剤
JPH05508860A (ja) 細胞接着制御環状化合物
US5610146A (en) 2,3-disubstituted isoxazolidines, a process for their preparation, agents containing them, and their use
US4301065A (en) Novel polypeptides having thymic activity or an antagonistic activity and processes for their synthesis
JPS59219257A (ja) 新規なペプチド誘導体とその製造方法並びにエラスタ−ゼ阻害剤としてのその使用
AU779779B2 (en) Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
US4631270A (en) Therapeutically useful pseudopeptides, compositions containing the same and methods of preparation and use
JPH0331298A (ja) プロリルエンドペプチターゼ阻害ペプチド
Nam et al. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases
US6511961B1 (en) Cyclic peptides and medicinal use thereof
JPH05271094A (ja) カルボキシメチル化キチン誘導体を用いる癌転移抑制剤
RU2010799C1 (ru) Производные пентапептидов
CN114450294B (zh) 具有mmp2抑制作用的多肽
Tiwari et al. Synthesis and evaluation of conformationally constrained peptide analogues as the Src SH3 domain binding ligands
MXPA01008337A (en) Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
RU2144038C1 (ru) Пептиды для ингибирования высвобождения пепсина, фармацевтическая композиция
HK1087126B (en) Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
US5276137A (en) Analgesic peptides with a trifluoronorvaline modification
Zanella SYNTHESIS OF PEPTIDOMIMETIC LIGANDS TARGETING CELL-SURFACE RECEPTORS INVOLVED IN TUMOR ANGIOGENESIS
JPH02157294A (ja) ペプチドおよびプロテアーゼ阻害剤
JPWO1999025731A1 (ja) 環状ペプチドおよびその医薬用途